Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00797953 · ClinicalTrials.gov registry record · Phase 2

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

A Phase 2 study of Angina Pectoris, sponsored by Tasly Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
124
Enrollment target
15
Study locations

NCT00797953 is a Phase 2 study of Angina Pectoris that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 124 participants, below the 901-participant average among 9 other Angina Pectoris trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00797953, a Phase 2 study of Angina Pectoris, has completed, sponsored by Tasly Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
124 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

Conditions Studied

Interventions

  • DRUG T89

Study Locations (15)

Texas

  • East Texas Cardiology - Houston
  • Northwest Houston Cardiology - Houston
  • Northwest Heart Center - Tomball

California

  • Robert M. Karns, A Medical Corporation - Beverly Hills
  • Inland Heart Doctors - Corona

Florida

  • Sunrise Medical Research - Lauderdale Lakes
  • Cardiovascular Research Center of South Florida - Miami

Arizona

  • Paradigm Clinical, Inc. - Tucson

Louisiana

  • Alexandria Cardiology Clinic - Alexandria

Michigan

  • Great Lakes Research Group, Inc - Bay City

New York

  • Marc Kozinn Associates - Williamsville

Oklahoma

  • Oklahoma Cardiovascular & Hypertension - Oklahoma City

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2007-02
Est. Completion 2010-01
Phase Phase 2

Sponsor

Tasly Pharmaceuticals

8 total trials

What the Registry Record Tells You About NCT00797953

The ClinicalTrials.gov registry entry for NCT00797953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 901-participant average among 9 other Angina Pectoris trials with a reported enrollment target (86% lower). The listed sponsor is Tasly Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Angina Pectoris appearing as the primary indexed condition, and to 1 intervention - of which T89 is the first listed.

NCT00797953 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00797953 about?

NCT00797953 is a clinical study titled "Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina". The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

What is the current status of trial NCT00797953?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-02. Estimated completion is 2010-01.

What conditions does trial NCT00797953 study?

This clinical trial studies the following conditions: Angina Pectoris.

What interventions are being tested in trial NCT00797953?

The interventions under investigation include: T89 (DRUG).

Who is sponsoring clinical trial NCT00797953?

This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00797953 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Angina Pectoris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.